November 19, 2024
Boehringer Ingelheim India and RED.Health ambulance services sign MOU to strengthen emergency stroke care in pre-hospital setup in India.
November 19, 2024
Boehringer Ingelheim India and RED.Health ambulance services sign MOU to strengthen emergency stroke care in pre-hospital setup in India.
August 23, 2024
Boehringer Ingelheim India and Vvaan Lifesciences Pvt Ltd announce strategic distribution partnership to expand pet portfolio reach.
July 12, 2024
Boehringer Ingelheim India enters into second collaboration with SIIC IIT Kanpur to support healthcare innovation
May 15, 2024
CDSCO approves SPEVIGO® (spesolimab) - the first treatment option for generalized pustular psoriasis flares in adults
April 18, 2024
Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India
February 14, 2024
Jardiance® (empagliflozin) now approved in India for the treatment of adults with chronic kidney disease
February 01, 2024
Boehringer Ingelheim India earns ‘‘Top Employer 2024’’ accolade for second consecutive year
September 20, 2023
Boehringer Ingelheim India joins forces with Pet Practitioners Association of Mumbai (PPAM) and Brihanmumbai Municipal Corporation (BMC) to ‘Stop Rabies’ in Mumbai
August 10, 2023
Boehringer Ingelheim expands animal health portfolio in India with the launch of NexGard® (afoxolaner) Small and Medium
June 26, 2023
Boehringer Ingelheim announces appointment of Gagandeep Singh as Managing Director and Head of Human Pharma for India
June 20, 2023
Boehringer Ingelheim India signs MoU with the Government of Maharashtra, to strengthen stroke care in the state
March 27, 2023
Boehringer Ingelheim India joins hands with Startup Incubation and Innovation Centre (SIIC), IIT Kanpur to support socially impactful innovations
June 06, 2022
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug
November 25, 2021
Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™
November 22, 2021
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India
September 01, 2021
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death by 21 percent, in adult patients of heart failure with preserved ejection fraction, with or without diabetes
June 15, 2021
Dr. V. Mohan Releases 9-point Action for People with Diabetes
May 26, 2021
Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine
May 18, 2021
Boehringer Ingelheim allocates COVID relief fund to support underserved communities and patients in India
March 25, 2021
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management
January 11, 2021
Boehringer Ingelheim announces appointment of Vani Manja as India Country MD
Media Contacts
Director, Communications, Boehringer Ingelheim India
Senior Manager, Communications, Boehringer Ingelheim India